Galectin Therapeutics Inc
General ticker "GALT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $141.0M
Galectin Therapeutics Inc follows the US Stock Market performance with the rate: 19.6%.
Estimated limits based on current volatility of 10.7%: low 0.88$, high 1.31$
Factors to consider:
- Current price 28.0% below estimated low
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [1.24$, 2.94$]
- 2024-12-30 to 2025-12-30 estimated range: [1.61$, 3.52$]
Financial Metrics affecting the GALT estimates:
- Negative: Non-GAAP EPS, $ of -0.74 <= 0.10
- Negative: Operating profit margin, % of -100 <= 1.03
- Negative: negative Net income
- Negative: Operating cash flow per share per price, % of -23.16 <= 2.35
- Positive: Interest expense per share, $ of 0.04 <= 0.14
- Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
Short-term GALT quotes
Long-term GALT plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $30.18MM | $38.35MM | $38.07MM |
| Operating Income | $-30.18MM | $-38.35MM | $-38.07MM |
| Non-Operating Income | $-0.35MM | $-0.42MM | $-2.99MM |
| Interest Expense | $0.49MM | $1.03MM | $2.56MM |
| R&D Expense | $23.82MM | $31.74MM | $32.13MM |
| Income(Loss) | $-30.53MM | $-38.78MM | $-41.07MM |
| Profit(Loss) | $-30.53MM | $-38.78MM | $-41.07MM |
| Stockholders Equity | $0.89MM | $-33.92MM | $-60.24MM |
| Assets | $41.83MM | $21.29MM | $28.20MM |
| Operating Cash Flow | $-24.31MM | $-31.06MM | $-32.97MM |
| Financing Cash Flow | $36.81MM | $10.00MM | $40.03MM |
| Earnings Per Share* | $-0.53 | $-0.66 | $-0.74 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.